Clinical Trial Update: Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated allogeneic hematopoietic stem cell transplantation from a single haploidentical donor for high-risk hematologic malignancies, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Hematopoietic/Lymphoid Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-06-07